

Scientific letter

Transcatheter Tricuspid Replacement With a Dedicated Self-expandable Valve: The GATE System**Reemplazo percutáneo de la válvula tricúspide con prótesis autoexpandible dedicada: sistema GATE****To the Editor,**

We present the case of a 76-year-old woman who was under follow-up for right heart failure at our hospital. The patient had a past medical history of hypertension, diabetes mellitus, permanent atrial fibrillation, and chronic kidney disease on dialysis. Her heart failure symptoms had worsened in recent months, requiring more frequent dialysis sessions as well as therapeutic paracentesis. Echocardiography showed severe tricuspid regurgitation (TR) secondary to annular dilatation, with a significant coaptation defect between the leaflets (Figure 1A, video 1 of the supplementary data). Left ventricular ejection fraction, pulmonary pressures, and right ventricular function were all normal. Following a multidisciplinary team discussion involving interventional cardiologists, cardiac imaging specialists, clinical cardiologists, anesthesiologists and cardiac surgeons, it was decided that conventional surgery would be very high risk (EuroScore II, 8.6%), but the patient was offered the option of transcatheter replacement of the native valve with a new tricuspid prosthesis, under compassionate use. The device is called the GATE system (NaviGate CSI; Lake Forest, California, United States) and is a bioprosthesis with xenopericardial valves mounted in a self-expanding Nitinol stent (Figure 1B). The Nitinol stent is

wider in the ventricular section, giving it a truncated conical shape that reduces the transvalvular gradient (this configuration generates a divergent nozzle into the right ventricular cavity that slows blood inflow and in turn reduces energy loss and flow separation, thus optimizing the gradient) and minimizes outflow tract obstruction, as there is little material protruding into the ventricle. Currently, it can be implanted via the jugular vein or via the right atrium with a minithoracotomy and is available in 5 sizes (36, 40, 44, 48, and 52 mm). To select the correct size, transesophageal echocardiography and cardiac computed tomography are required to measure the tricuspid annulus as precisely as possible and to establish the relationship of the annulus to the right coronary artery (Figure 1C). It is recommended to use a prosthesis that is slightly larger than the annulus (< 5–10%). In the case presented here, the mean diameter of the annulus on both imaging modalities was 42.2 mm, so a 44 mm prosthesis was used.

The procedure was conducted under general anesthetic and transesophageal echocardiographic guidance. A guide catheter was positioned with an intracoronary guidewire in the right coronary artery to mark the tricuspid annulus and to serve as a reference during implantation. In addition, a high-support guidewire was positioned in the left ventricle in case pacing was required during the procedure (it was not) and a pigtail catheter was positioned in the right ventricle to assess the TR and the final result (Figure 2A). In this case, transatrial access was used, as the caliber of the jugular vein was too small for the introducer sheath. Once access was obtained via the fourth intercostal space, a high-support guidewire




Figure 1. Imaging study. A: transesophageal echocardiography showing severe tricuspid regurgitation with separation (asterisk). B: GATE prosthesis. C: computed tomography study to measure the tricuspid annulus.

SEE RELATED CONTENT:

<https://doi.org/10.1016/j.rec.2019.06.003>

<https://doi.org/10.1016/j.rec.2019.02.005>

1885-5857/© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.




Figure 2. Procedure. A: guide catheter and intracoronary guidewire in the right coronary artery, high-support guidewire in the left ventricle and pigtail in the right ventricle. B: undamaged coronary artery following implantation. C: implanted valve, with no residual regurgitation or outflow tract obstruction. D: echocardiographic result following implantation.

was introduced into the right ventricle and used to position the device introducer (42 Fr). The valve deployment system was then advanced, and once in position and completely coaxial to the annular plane, the valve was deployed under echocardiographic and fluoroscopic guidance. Once unfolded, transesophageal echocardiography and right ventriculography were used to check the result and to check for right coronary artery damage (Figure 2B, 2C, and 2D and video 2 of the supplementary data). Following successful implantation, the patient was extubated at 6 hours, and subsequently discharged from hospital. At the 3-month follow-up, the patient showed considerable clinical improvement, with no evidence of congestion (edema or ascites), and required fewer dialysis sessions and less volume extraction. Follow-up echocardiography at this point showed that the prosthesis was functioning normally, with no gradient or significant residual regurgitation (video 3 of supplementary data).

Patients with TR and secondary heart failure are often very symptomatic due to the reduced cardiac output and peripheral and abdominal congestion. In addition, the presence of moderate or severe TR is associated with increased mortality, independently of the biventricular function or pulmonary pressures.¹ Current data support tricuspid repair when left heart surgical procedures are planned; however, reoperation for persistent or recurrent TR is associated with high morbidity and mortality.^{2,3} In such cases, therefore, transcatheter tricuspid repair techniques are an alternative to conventional surgery.⁴ Of these, the technique that has accumulated the most experience is the MitraClip in a tricuspid position.⁵ However, there are some anatomical determinants that make its use difficult, such as very large (> 7 mm) coaptation defects or the presence of a regurgitant jet outside the anteroseptal area. In these cases, other devices, such as that presented here, may have their place. The GATE system is the first that completely

replaces the valve in its orthotopic position and thus completely eliminates the TR. The preclinical data on this device are good (implantation safety and sufficient data on the gradient, absence of outflow tract obstruction, perivalvular leaks, coronary artery damage and leaflet thrombosis or calcification), and some 30 cases have been performed worldwide.⁶ Longer follow-up is needed to confirm the results, but it is a promising technique.

APPENDIX. SUPPLEMENTARY DATA

Supplementary data associated with this article can be found in the online version, at <https://doi.org/10.1016/j.rec.2019.02.005>.

Rodrigo Estévez-Loureiro,* Vanessa Moñivas, Carlos Arellano-Flores, Alberto Forteza, Carlos Martín, and Javier Goicolea

Departamento de Cardiología, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

*Corresponding author:

E-mail address: roiestevezh@hotmail.com (R. Estévez-Loureiro).

Available online 14 March 2019

REFERENCES

1. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. *J Am Coll Cardiol.* 2004;43:405–409.

2. Kim YJ, Kwon DA, Kim HK, et al. Determinants of surgical outcome in patients with isolated tricuspid regurgitation. *Circulation*. 2009;120:1672–1678.
3. McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for failure. *J Thorac Cardiovasc Surg*. 2004;127:674–685.
4. Campelo-Parada F, Lairez O, Carrié D. Percutaneous Treatment of the Tricuspid Valve Disease: New Hope for the “Forgotten” Valve. *Rev Esp Cardiol*. 2017;70:856–866.
5. Taramasso M, Hahn RT, Alessandrini H, et al. The International Multicenter TriValve Registry: which patients are undergoing transcatheter tricuspid repair? *JACC Cardiovasc Interv*. 2017;10:1982–1990.

6. Navia JL, Kapadia S, Elgharably H, et al. Transcatheter tricuspid valve implantation of NaviGate bioprosthesis in a preclinical model. *JACC Basic Transl Sci*. 2018;3:67–79.

<https://doi.org/10.1016/j.rec.2019.02.005>
1885-5857/

© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Percutaneous Tricuspid Valve Replacement Using a Valved Bioprosthesis



Tratamiento percutáneo de la insuficiencia tricuspídea mediante una endoprótesis valvulada

To the Editor:

Severe tricuspid regurgitation (TR) is an uncommon condition associated with a poor prognosis^{1,2} and high recurrence, morbidity, and mortality rates with conventional surgical treatment.^{3,4} Several alternative therapies involving percutaneous techniques have been recently proposed for TR.^{5,6} One such procedure is implantation of a bicaval-anchored valved endoprosthesis, custom-made for the patient's anatomy (Tricento transcatheter prosthesis) (Figure 1) and designed to prevent retrograde flow toward the venae cavae. The valve is inserted through a 24-Fr delivery system via a transfemoral venous access. The device can be repositioned and retrieved up to the time the valve system is deployed.

We report the first clinical case in Spain of successful percutaneous implantation of a Tricento endoprosthesis in the tricuspid position to treat severe TR causing heart failure in New York Heart Association functional class III IV and overt systemic congestion despite optimal medical treatment.

The patient was an 81-year-old woman with hypertension, dyslipidemia, and chronic atrial fibrillation receiving anticoagulant therapy. Transthoracic echocardiography (video 1 of the supplementary data) detected massive functional TR, a moderately dilated right ventricle with mild-moderate dysfunction, and inverted flow toward the venae cavae. She had no other significant valve disease, and the left ventricular ejection fraction was normal.

With the use of computed tomography, the dimensions of the 2 venae cavae were determined, and the outlets of the suprahepatic veins were confirmed to be more than 1 cm from the outlet of the inferior vena cava (IVC) in the right atrium.

The patient's risk of operative mortality estimated with the Euroscore II was 3.1% and the risk of morbidity and mortality by




Figure 1. A, expanded Tricento valved prosthesis showing its components. B, gradual release mechanism in various phases up to complete expansion. C, angiography sequence showing implantation and release to complete expansion. D, computed tomography image following implantation, showing correct positioning: the pillars of the valve component are facing the plane of the native tricuspid valve and the right ventricular inflow tract.